HAYWARD, Calif.--(BUSINESS WIRE)--
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the
Company will release its fourth quarter and full year 2013 financial
results on Thursday, February 20, 2014, after the close of the U.S.
financial markets. The Company will host a conference call and live
webcast with the investment community at 4:30 p.m., Eastern Time on
February 20, 2014.
The financial results and live webcast will be accessible through the
Investor Relations section of the Company's Web site, www.impaxlabs.com.
To access the call through a conference line, dial (877) 356-3814 (in
the U.S.) and (706) 758-0033 (international callers). The conference ID
is 47654631.
A replay of the conference call will be available for seven days shortly
after the call. To access the replay, dial (855) 859-2056 (in the U.S.)
and (404) 537-3406 (international callers). The access code for the
replay is 47654631.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. (Impax) is a technology based specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of central nervous
system disorder branded products. Impax markets its generic products
through its Global Pharmaceuticals division and markets its branded
products through the Impax Pharmaceuticals division. Additionally, where
strategically appropriate, Impax develops marketing partnerships to
fully leverage its technology platform and pursues partnership
opportunities that offer alternative dosage form technologies, such as
injectables, nasal sprays, inhalers, patches, creams and ointments. For
more information, please visit the Company's Web site at: www.impaxlabs.com.
Source: Impax Laboratories, Inc.